Connected Care for hEDS & Complex Chronic Illness
Hypermobility (hEDS/HSD) · MCAS · Dysautonomia & POTS · Hormonal Health · Neurodiversity
Beyond the Diagnosis: Recognizing the Overlap
At Evergreen Women & Family Wellness, we recognize that living with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD) often means navigating a medical picture that extends well beyond the joints. Many patients also experience dysautonomia such as POTS, mast cell–related symptoms, gastrointestinal and nutritional challenges, chronic pain, fatigue, and neurodivergence. Too often, these are managed in isolation, leaving patients to coordinate their own care between specialists.
Our telemedicine practice takes a collaborative, whole-person approach. We work alongside patients and their established care teams, including cardiologists, neurologists, gastroenterologists, allergists, physical and occupational therapists, and nutrition professionals, across multiple states. We help bridge gaps between specialties, facilitate communication, streamline complex medication regimens, and bring a cohesive perspective to the treatment plan.
The Missing Piece: Hormones
Most care for hEDS and related conditions overlooks one of the most consistent patterns patients describe: symptoms that change with hormonal shifts. Research supports what many already know from experience:
hEDS symptoms often track the hormonal life cycle. In a large cohort of women with hEDS, about half reported symptoms worsening at puberty, and a subset noted flares before menstruation, postpartum, and with certain contraceptives. Some improved with hormonal treatment, and about one in five reported improvement after menopause (Hugon-Rodin et al., Orphanet Journal of Rare Diseases, 2016)
POTS symptoms commonly fluctuate across the menstrual cycle, often worsening when estrogen and progesterone fall before and during menses. About 90% of people with POTS are female, and onset often follows puberty (Bryarly et al., Journal of the American College of Cardiology, 2019; American College of Obstetricians and Gynecologists, 2020).
Mast cells carry estrogen and progesterone receptors. Laboratory studies show sex hormones can influence mast cell activity, and several mast cell–related conditions, such as asthma and migraine, change with the cycle and differ between women and men (Zierau et al., Frontiers in Immunology, 2012; Meyer and Zenclussen, American Journal of Reproductive Immunology, 2018).
Hormones affect ligaments and connective tissue. A recent systematic review found that estrogen, relaxin, pregnancy, contraception, and menopause may affect ligament properties (Gilmer et al., American Journal of Sports Medicine, 2025).
ADHD symptoms may shift with falling estrogen, including across the menstrual cycle, an emerging area that is especially relevant during perimenopause (Eng et al., Hormones and Behavior, 2024).
These are real, documented patterns, though high-quality treatment trials in this population are still lacking. That is why we take a careful, individualized approach. With extensive experience in perimenopause and menopause care, we evaluate how menstrual cycles, contraception, pregnancy and postpartum, perimenopause, and menopause may be affecting joint stability, pain, dysautonomia, mast cell symptoms, sleep, mood, and cognition. We then consider evidence-based options, including cycle-informed symptom planning, hormonal contraception or progestin strategies, menopausal hormone therapy when appropriate, and local vaginal estrogen for genitourinary symptoms, while weighing each patient's risks and other conditions.
The Interwoven Conditions We Treat
We recognize that these conditions frequently co-exist, amplifying symptoms and complicating diagnosis.
1
Mast Cell Activation Syndrome (MCAS)
An immune disorder where specialized mast cells inappropriately release large amounts of inflammatory chemicals (mediators).
Core Feature: Uncontrolled, excessive release of inflammatory mediators (like histamine, tryptase).
Common Symptoms: Episodic flushing, hives, severe allergic-like reactions, digestive issues, and cardiovascular symptoms (tachycardia, low blood pressure).
2
Ehlers-Danlos Syndrome (EDS)
A genetic disorder affecting the body's connective tissue due to faulty collagen production, leading to fragility and laxity.
Core Feature: Defective or fragile connective tissue ("the body's glue").
Common Symptoms: Chronic joint pain, frequent joint dislocations/subluxations, overly stretchy and easily bruised skin, and a frequent overlap with dysautonomia and GI symptoms.
3
Dysautonomia/ POTS
Dysregulation of the autonomic nervous system, which controls heart rate, blood pressure, digestion, and temperature.
Core Feature: Common in hEDS/HSD and includes POTS (the most frequent form), orthostatic hypotension, fainting, GI dysmotility, and small fiber neuropathy.
Common Symptoms: Dizziness, palpitations, fatigue, brain fog, and exercise intolerance, often worsened by heat, meals, and the premenstrual phase.
4
Neurodiversity (ASD, ADHD)
Natural variation in how the brain processes information, attention, and sensory input.
Core Feature: Natural human variation in neurological development and function.
Clinical Link: Joint hypermobility is more common in autistic people and people with ADHD, and that co-occurring dysautonomia, pain, and GI symptoms are frequent. The reasons for this overlap are still being studied. Neurodivergent patients also deserve care that adapts to sensory and communication needs.
The Overlap: Why This Matters to Your Care
The most challenging cases often involve the convergence of these illnesses. At Evergreen, we specifically target the common threads binding them together
hEDS, POTS, and MCAS frequently co-occur. Studies report higher rates of POTS and MCAS in people with hEDS/HSD; in one survey of more than 600 patients with hEDS/HSD, over a third reported a POTS diagnosis (American Gastroenterological Association, 2025). The biological connections are not yet fully understood; proposed contributors include vascular laxity, small fiber neuropathy, and immune factors.
Symptoms amplify each other. Mast cell–related vasodilation can worsen orthostatic symptoms, and dysautonomia can worsen fatigue, GI function, and pain, so treating one condition often helps another.
Hormones are a common thread. Puberty, the menstrual cycle, postpartum, and perimenopause can shift symptoms across all of these conditions at once, yet hormonal health is rarely addressed in complex chronic illness care.
Brain fog, fatigue, headaches, anxiety, and sleep disruption are shared across these conditions and can be driven by orthostatic intolerance, pain, poor sleep, mast cell symptoms, medications, and hormonal change. We look at each contributor rather than assuming a single cause.
Management Strategies
-
Treatment is individualized and guided by symptom response. Medications are usually added one at a time so the effect of each can be judged.
Trigger awareness: Identifying personal triggers (such as heat, alcohol, stress, certain foods, or medications) and reducing exposure where practical, without unnecessarily restrictive diets.
First-line medications: Non-sedating H1 antihistamines combined with H2 blockers.
Additional options: Mast cell stabilizers (oral cromolyn sodium, or compounded ketotifen) and leukotriene blockers (such as montelukast), tailored to which symptoms predominate.
Supplements: Vitamin C, vitamin D (dosed to blood levels), and quercetin are sometimes used as add-ons. Evidence for them is limited.
Diet: A short, structured trial of a low-histamine or elimination diet when symptoms suggest food triggers, with nutrition support so the diet stays nutritionally adequate.
Safety: An epinephrine auto-injector and an action plan for patients with a history of anaphylaxis.
Co-management: Allergy/Immunology for confirming the diagnosis, ruling out systemic mastocytosis and other mast cell disorders, and advanced therapies such as biologics. Gastroenterology for significant GI symptoms.
-
Management focuses on joint stability, function, pain control, and treating associated conditions.
Physical/Occupational Therapy: Gradual strengthening, proprioception (body awareness) training, and joint protection, avoiding end-range stretching. Progression is slow to prevent flares.
Activity: Low-impact exercise (such as swimming, recumbent cycling, or Pilates-based programs) with activity pacing to manage fatigue.
Pain management: A multimodal, non-opioid approach that includes physical therapy, topical agents, sleep optimization, and targeted procedures when appropriate.
Bracing and supports: Used selectively for unstable joints. Ring splints and other orthotics may help with hand function.
Co-management: Rheumatology to rule out inflammatory arthritis or other connective tissue conditions. Genetics when features suggest another EDS type or heritable disorder. Orthopedics for recurrent dislocations, with surgery considered carefully because healing and outcomes can differ in hEDS.
-
Non-medication measures are the foundation of treatment and are often enough on their own.
Fluids and salt: Increased fluid and salt intake, or oral rehydration solutions, when kidney function, blood pressure, and heart status allow.
Compression: High-waisted compression garments or abdominal binders to reduce blood pooling.
Reconditioning: A gradual exercise program that starts with recumbent or horizontal activity (rowing, recumbent bike, swimming) and progresses to upright activity.
Daily strategies: Smaller, more frequent meals with fewer refined carbohydrates. Avoiding heat and prolonged standing. Counter-maneuvers such as leg crossing, calf pumping, and hand grip. Raising the head of the bed.
Medications, when needed: Chosen by symptom pattern, for example low-dose beta-blockers or ivabradine for heart rate, and midodrine or fludrocortisone for low blood pressure.
Co-management: Cardiology or Neurology for autonomic testing and medications. Gastroenterology for dysmotility.
-
Care is neuro-affirming. It builds on strengths, provides accommodations, and treats co-occurring medical and mental health conditions.
Occupational therapy: Support for sensory processing differences, sensory regulation strategies, and functional skills.
Executive function support: Coaching and practical tools for planning, organization, and attention, plus guidance for parents of neurodivergent children.
Medication management: Evidence-based treatment of ADHD, anxiety, depression, and sleep problems, with attention to medication sensitivities and interactions with heart rate, blood pressure, and dysautonomia treatments.
Physical health connections: Treating co-occurring pain, GI problems, sleep disruption, hormonal changes, and dysautonomia, which can increase sensory overload, irritability, and fatigue.
Healthcare accessibility: Visit formats, communication styles, and planning adapted to the individual's sensory and processing needs.
Co-management: Psychiatry and neuro-affirming therapy, including CBT adapted for neurodivergent individuals.
-
CIRS is not yet a validated diagnosis in mainstream medicine, and its treatment protocols have not been tested in controlled trials. Our approach puts evaluation and evidence-informed steps first.
Rule out other causes: Fatigue, brain fog, and pain overlap with thyroid disease, anemia, sleep disorders, autoimmune disease, depression, long COVID, and the other conditions on this page, so these are evaluated first.
Environmental assessment: When a water-damaged building is a concern, professional inspection and remediation of moisture and mold sources, which is clearly supported for respiratory and allergic health.
Recognized mold-related illness: Treatment of established conditions such as asthma, allergic rhinitis, hypersensitivity pneumonitis, and allergic fungal disease.
Binders and specialized protocols: Shared decision-making about therapies such as cholestyramine.
Supportive care: Sleep, pacing, nutrition, and autonomic strategies to address symptom burden.
Co-management: Environmental professionals, Allergy/Immunology, and Pulmonology as indicated.